Compare Novo Nordisk A/S (NVO) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs NEOS S&P 500 High Income ETF — how do they compare? Novo Nordisk A/S trades at $46.07 (market cap $207.85B), while NEOS S&P 500 High Income ETF trades at $54.18. The key difference: Novo Nordisk A/S pays a 3.81% dividend while NEOS S&P 500 High Income ETF pays none, and NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | SPYI | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $63.98 | $54.19 |
52-Week Low | $35.29 | $47.98 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
SPYI trades at $54.19 with a flat 24-hour change, supported by a bullish technical signal from moving averages. The ETF focuses on generating high income through an options overlay on the S&P 500, with recent dividends around $0.53-$0.54 per share. News highlights its 11.7% yield appeal for retirement income, though some articles caution about fee gaps and yield sustainability.
The outlook hinges on volatility-driven income generation, offering tax-efficient distributions but facing risks from declining market volatility and potential principal erosion. Investors are drawn to the high yield for retirement cash flow, yet must weigh the trade-off between income and long-term capital appreciation in a competitive covered call ETF space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
